Fetal aqueductal stenosis is the leading cause of congenital
hydrocephalus and effects 2-4 infants per 10,000 births. The condition can
currently be diagnosed via ultrasound as early as 20 weeks of gestation.
However, no treatment is available until after birth, leading to
increased risks of obstetric complications for the mother and long-term
complications for the child. VASFAS is a shunt that will be placed in the fetus
through the maternal abdominal wall under ultrasound guidance allowing for
immediate treatment of hydrocephalus in-utero. A potential market of $140
million has been estimated and no other fetal shunts for hydrocephalus
treatment are currently available on the market.